MME and acute lymphoblastic leukemia: The KMT2A-rearranged ALL is associated with the precursor B-cell ALL immunophenotype with the expression of CD19 antigen, lack of CD10, and also co-expression of myeloid markers such as CD15, CD33, and CD68 [111,112].